Top

Published in:

01-07-2017 | Original Article

Identification of key genes and construction of microRNA–mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis

Authors: Hongyu Gao, Huihan Wang, Wei Yang

Published in: International Journal of Hematology | Issue 1/2017

Abstract

Multiple myeloma (MM) is a common hematological malignancy. To identify key genes and microRNAs in MM, we downloaded two gene expression profiles (GSE16558 and GSE47552) and two microRNA expression profiles (GSE17498 and GSE16558) from the Gene Expression Omnibus (GEO) database. A total of 596 differentially expressed genes (DEGs) and 39 differentially expressed microRNAs (DEMs) were screened out. Pathway analysis showed that upregulated genes were mainly enriched in the “B cell receptor signaling pathway”, “Cell cycle” and “NF-kappa B signaling pathway”, whereas downregulated genes were mainly enriched in the “Ribosome”, “FoxO signaling pathway” and “p53 signaling pathway”. We subsequently constructed a protein–protein interaction network of DEGs consisting of 277 genes and 563 interactions. In addition, 32 genes with high degrees in the network were identified as hub genes in MM, e.g. HDAC2, RBBP4, CREB1, and RB1. Additionally, we constructed a microRNA–mRNA regulatory network depicting interactions between DEMs and their targets, including the miR-135b–GADD45A and miR-148a–USPL1 pairs. In conclusion, the results of this data mining and integration help reveal the molecular basis of MM pathogenesis as well as potential biomarkers and therapeutic targets for MM diagnosis and treatment.

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–60. doi:10.1056/NEJMra1011442.CrossRefPubMed

Landgren O, Kristinsson SY, Goldin LR, Caporaso NE, Blimark C, Mellqvist UH, et al. Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood. 2009;114(4):791–5. doi:10.1182/blood-2008-12-191676.CrossRefPubMedPubMedCentral

Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997. doi:10.1038/ncomms7997.CrossRefPubMedPubMedCentral

Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91–101. doi:10.1016/j.ccr.2013.12.015.CrossRefPubMedPubMedCentral

Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997. doi:10.1038/ncomms3997.CrossRefPubMedPubMedCentral

Rio-Machin A, Ferreira BI, Henry T, Gomez-Lopez G, Agirre X, Alvarez S, et al. Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. Leukemia. 2013;27(4):925–31. doi:10.1038/leu.2012.302.CrossRefPubMed

Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009;114(25):e20–6. doi:10.1182/blood-2009-08-237495.CrossRefPubMed

Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):654–69. doi:10.1002/wsbm.89.CrossRefPubMed

Dimopoulos K, Gimsing P, Gronbaek K. Aberrant microRNA expression in multiple myeloma. Eur J Haematol. 2013;91(2):95–105. doi:10.1111/ejh.12124.CrossRefPubMed

10.

Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9(11):1511–20. doi:10.4161/15592294.2014.983367.CrossRefPubMedPubMedCentral

11.

Brandl A, Heinzel T, Kramer OH. Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell. 2009;101(4):193–205. doi:10.1042/BC20080158.CrossRefPubMed

12.

Kramer OH. HDAC2: a critical factor in health and disease. Trends Pharmacol Sci. 2009;30(12):647–55. doi:10.1016/j.tips.2009.09.007.CrossRefPubMed

13.

Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016;104(3):300–9. doi:10.1007/s12185-016-2008-0.CrossRefPubMed

14.

Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut. 2009;58(10):1399–409. doi:10.1136/gut.2009.180711.CrossRefPubMed

15.

Hanigan CL, Van Engeland M, De Bruine AP, Wouters KA, Weijenberg MP, Eshleman JR, et al. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology. 2008;135(5):1654–64. doi:10.1053/j.gastro.2008.07.078.CrossRefPubMed

16.

Wagner T, Brand P, Heinzel T, Kramer OH. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochim Biophys Acta. 2014;1846(2):524–38. doi:10.1016/j.bbcan.2014.07.010.PubMed

17.

Zhao J, Xie C, Edwards H, Wang G, Taub JW, Ge Y. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Oncotarget. 2016;. doi:10.18632/oncotarget.14062.

18.

Todd MA, Picketts DJ. PHF6 interacts with the nucleosome remodeling and deacetylation (NuRD) complex. J Proteome Res. 2012;11(8):4326–37. doi:10.1021/pr3004369.CrossRefPubMed

19.

Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002;16(22):2893–905. doi:10.1101/gad.1035902.CrossRefPubMedPubMedCentral

20.

Furuyama T, Dalal Y, Henikoff S. Chaperone-mediated assembly of centromeric chromatin in vitro. Proc Natl Acad Sci USA. 2006;103(16):6172–7. doi:10.1073/pnas.0601686103.CrossRefPubMedPubMedCentral

21.

Zhang W, Tyl M, Ward R, Sobott F, Maman J, Murthy AS, et al. Structural plasticity of histones H3–H4 facilitates their allosteric exchange between RbAp48 and ASF1. Nat Struct Mol Biol. 2013;20(1):29–35. doi:10.1038/nsmb.2446.CrossRefPubMed

22.

Li Y, Xu D, Bao C, Zhang Y, Chen D, Zhao F, et al. MicroRNA-135b, a HSF1 target, promotes tumor invasion and metastasis by regulating RECK and EVI5 in hepatocellular carcinoma. Oncotarget. 2015;6(4):2421–33. doi:10.18632/oncotarget.2965.CrossRefPubMed

23.

He Y, Wang J, Wang J, Yung VY, Hsu E, Li A, et al. MicroRNA-135b regulates apoptosis and chemoresistance in colorectal cancer by targeting large tumor suppressor kinase 2. Am J Cancer Res. 2015;5(4):1382–95.PubMedPubMedCentral

24.

Wu W, Wang Z, Yang P, Yang J, Liang J, Chen Y, et al. MicroRNA-135b regulates metastasis suppressor 1 expression and promotes migration and invasion in colorectal cancer. Mol Cell Biochem. 2014;388(1–2):249–59. doi:10.1007/s11010-013-1916-z.CrossRefPubMed

25.

Hua K, Jin J, Zhao J, Song J, Song H, Li D, et al. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2. Int J Oncol. 2016;48(5):1997–2006. doi:10.3892/ijo.2016.3405.PubMed

26.

Hoffman B, Liebermann DA. Gadd45 modulation of intrinsic and extrinsic stress responses in myeloid cells. J Cell Physiol. 2009;218(1):26–31. doi:10.1002/jcp.21582.CrossRefPubMed

27.

Liebermann DA, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A, Hoffman B. Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncogenesis. 2011;16(1–2):129–40.CrossRefPubMedPubMedCentral

28.

Guo W, Dong Z, Guo Y, Chen Z, Kuang G, Yang Z. Methylation-mediated repression of GADD45A and GADD45G expression in gastric cardia adenocarcinoma. Int J Cancer. 2013;133(9):2043–53. doi:10.1002/ijc.28223.CrossRefPubMed

29.

Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, Reis IM, et al. Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009;69(4):1527–35. doi:10.1158/0008-5472.CAN-08-3609.CrossRefPubMed

30.

Amente S, Zhang J, Lavadera ML, Lania L, Avvedimento EV, Majello B. Myc and PI3 K/AKT signaling cooperatively repress FOXO3a-dependent PUMA and GADD45a gene expression. Nucleic Acids Res. 2011;39(22):9498–507. doi:10.1093/nar/gkr638.CrossRefPubMedPubMedCentral

31.

Krzeminski P, Sarasquete ME, Misiewicz-Krzeminska I, Corral R, Corchete LA, Martin AA, et al. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochim Biophys Acta. 2015;1849(3):353–66. doi:10.1016/j.bbagrm.2014.12.002.CrossRefPubMed

32.

Bi C, Chung TH, Huang G, Zhou J, Yan J, Ahmann GJ, et al. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma. Oncotarget. 2015;6(28):26508–18. doi:10.18632/oncotarget.4769.CrossRefPubMedPubMedCentral

33.

Porstner M, Winkelmann R, Daum P, Schmid J, Pracht K, Corte-Real J, et al. miR-148a promotes plasma cell differentiation and targets the germinal center transcription factors Mitf and Bach2. Eur J Immunol. 2015;45(4):1206–15. doi:10.1002/eji.201444637.CrossRefPubMed

34.

Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, et al. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer. 2013;119(11):1985–93. doi:10.1002/cncr.28002.CrossRefPubMedPubMedCentral

35.

Zheng G, Xiong Y, Xu W, Wang Y, Chen F, Wang Z, et al. A two-microRNA signature as a potential biomarker for early gastric cancer. Oncol Lett. 2014;7(3):679–84. doi:10.3892/ol.2014.1797.PubMedPubMedCentral

36.

Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, et al. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One. 2012;7(10):e46684. doi:10.1371/journal.pone.0046684.CrossRefPubMedPubMedCentral

37.

Hanoun N, Delpu Y, Suriawinata AA, Bournet B, Bureau C, Selves J, et al. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem. 2010;56(7):1107–18. doi:10.1373/clinchem.2010.144709.CrossRefPubMed

38.

Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8(12):947–56. doi:10.1038/nrm2293.CrossRefPubMed

39.

Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 2010;11(12):861–71. doi:10.1038/nrm3011.CrossRefPubMedPubMedCentral

40.

Johnson ES. Protein modification by SUMO. Annu Rev Biochem. 2004;73:355–82. doi:10.1146/annurev.biochem.73.011303.074118.CrossRefPubMed

41.

Hay RT. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. 2007;17(8):370–6. doi:10.1016/j.tcb.2007.08.002.CrossRefPubMed

42.

Bawa-Khalfe T, Yeh ET. SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer. 2010;1(7):748–52. doi:10.1177/1947601910382555.CrossRefPubMedPubMedCentral

43.

Schulz S, Chachami G, Kozaczkiewicz L, Winter U, Stankovic-Valentin N, Haas P, et al. Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMBO Rep. 2012;13(10):930–8. doi:10.1038/embor.2012.125.CrossRefPubMedPubMedCentral

44.

Bermejo JL, Kabisch M, Dunnebier T, Schnaidt S, Melchior F, Fischer HP, et al. Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases. Int J Cancer. 2013;133(2):362–72. doi:10.1002/ijc.28040.CrossRefPubMed

Title: Identification of key genes and construction of microRNA–mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis
Authors: Hongyu Gao
Huihan Wang
Wei Yang
Publication date: 01-07-2017
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 1/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-017-2216-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

First case report of hemophilia B Leyden in Japan

Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan

Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation

Perisinusoidal bone marrow involvement by lymphoma

Potentially life-threatening coagulopathy associated with simultaneous reduction in coagulation and fibrinolytic function in pediatric acute leukemia after hematopoietic stem-cell transplantation

Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer